Swedish startup Epigenovo is commercializing scFFPE‑ATAC, a high‑throughput single‑cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) tissues. The Uppsala University spinout demonstrated proof‑of‑concept in Nature Communications and is raising funds to kit the assay and offer services to translational researchers. The scFFPE‑ATAC workflow combines a custom FFPE‑Tn5 transposase with combinatorial indexing and DNA damage rescue to generate single‑cell accessibility profiles from archived clinical samples. Epigenovo claims the method yields tens of millions of cell barcodes per run, enabling epigenetic profiling of retrospective clinical cohorts. If validated at scale, the assay could unblock clinical translation of chromatin biomarkers by making archived pathology specimens analyzable at single‑cell resolution. Investors and translational labs will watch commercialization progress and kit reproducibility.